2024 Fellows Courses

Breakfast Program: Targeting Lipids to Improve Outcomes in Your Cath Patients

At the end of this activity, participants will be able to: 

  1. Discuss testing strategies for lipoprotein (a), apoB, and lipid analysis in contemporary practice.
  2. Recognize system-level gaps and explore system-based strategies to provide optimal guideline directed lipid-lowering therapy for secondary prevention.
  3. Clarify when to use statins and non-statin therapies to achieve lipid targets.
  4. Empower patients with knowledge necessary to make decisions about setting and achieving their target lipid levels.

Sponsored by SCAI. Supported by Esperion.

Genetic Basis of Lipoprotein (a), ApoB, and Lipid Analysis in Contemporary Practice
David Zidar, M.D., Ph.D., FSCAI, Case Western Reserve University School of Medicine, Pepper Pike, OH
Undertreatment and Opportunity in Lipid Lowering Therapy for Patients with Coronary and Peripheral Artery Disease
Subhash Banerjee, M.D., FSCAI, Baylor Scott & White Heart and Vascular Hospital - Dallas, Dallas, TX
Statins and Non-statin Therapy: For Whom and When
Marc P. Bonaca, MD, MPH, University of Colorado School of Medicine, Aurora, CO
Championing Strategies to Improve Outcomes for PAD and Polyvascular Disease
Matthew C. Bunte, M.D., FSCAI, The University of Missouri – Kansas City, Leawood, KS
Panel Discussion